21594-54-7

Usage

Uses

Used in Pharmaceutical Industry:
6-Nitrooxazolo[4,5-b]pyridin-2(3H)-one is used as a pharmaceutical intermediate for the development of new drugs. Its potential biological activity and unique structure make it a promising candidate for the creation of novel therapeutic agents.
Used in Research Applications:
6-Nitrooxazolo[4,5-b]pyridin-2(3H)-one is used as a research tool in chemical biology. Its unique properties and structure allow researchers to study its interactions with biological systems and explore its potential applications in various fields.
Used in Organic Synthesis:
6-Nitrooxazolo[4,5-b]pyridin-2(3H)-one is used as a building block in organic synthesis. Its versatile structure allows for the creation of a wide range of compounds with potential applications in various industries.
Used in Drug Discovery:
6-Nitrooxazolo[4,5-b]pyridin-2(3H)-one is used in drug discovery efforts to identify new therapeutic agents. Its potential biological activity and unique structure make it a valuable compound for the development of innovative treatments.

Upstream product

• 16867-03-1 2-amino-3-hydroxypyridine 
• 60832-72-6 2,3-dihydro[1,3]oxazolo[4,5-b]pyridin-2-one 

Downstream Products

• 908248-27-1 2-amino-5-nitropyridin-3-ol 

Relevant academic research and scientific papers

NOVEL ULK1 INHIBITORS AND METHODS USING SAME

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

FUSED IMIDAZOLE COMPOUNDS

The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.